Financhill
Sell
35

VXRT Quote, Financials, Valuation and Earnings

Last price:
$0.44
Seasonality move :
0.49%
Day range:
$0.42 - $0.47
52-week range:
$0.29 - $1.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.00x
P/B ratio:
2.19x
Volume:
3.7M
Avg. volume:
6.9M
1-year change:
-35.35%
Market cap:
$100M
Revenue:
$28.7M
EPS (TTM):
-$0.27

Analysts' Opinion

  • Consensus Rating
    Vaxart has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $4.67, Vaxart has an estimated upside of 965.45% from its current price of $0.44.
  • Price Target Downside
    According to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.44.

Fair Value

  • According to the consensus of 3 analysts, Vaxart has 965.45% upside to fair value with a price target of $4.67 per share.

VXRT vs. S&P 500

  • Over the past 5 trading days, Vaxart has underperformed the S&P 500 by -19.3% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Vaxart does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Vaxart has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Vaxart reported revenues of $20.9M.

Earnings Growth

  • Vaxart earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Vaxart reported earnings per share of -$0.07.
Enterprise value:
58M
EV / Invested capital:
--
Price / LTM sales:
2.00x
EV / EBIT:
--
EV / Revenue:
1.22x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.72x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-41.87%
Net Income Margin (TTM):
-122.63%
Return On Equity:
-94.14%
Return On Invested Capital:
-94.14%
Operating Margin:
-71.54%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue -- $9.3M $47.4M $2.2M $20.9M
Gross Profit -- -- -- -- --
Operating Income -$111.1M -$81.8M -$57.2M -$24.1M -$14.9M
EBITDA -$99.8M -$70.7M -$45.7M -$21.4M -$12.3M
Diluted EPS -$0.83 -$0.53 -$0.27 -$0.14 -$0.07
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $175.4M $154.2M $75.8M $44.3M $62.6M
Total Assets $205.9M $200.4M $129.9M $88.7M $158.6M
Current Liabilities $11.6M $11M $15.7M $14.1M $98.5M
Total Liabilities $29.6M $34M $40.1M $33M $112.9M
Total Equity $176.2M $166.4M $89.8M $55.7M $45.6M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$94.1M -$67.2M -$33.2M -$21.2M -$9.6M
Cash From Investing $1.3M $13.5M -$3.1M -$5M $13.2M
Cash From Financing $17.8M $32M $38.2M $18.2M -$164K
Free Cash Flow -$103.6M -$67.9M -$33.7M -$21.3M -$9.7M
VXRT
Sector
Market Cap
$100M
$33.7M
Price % of 52-Week High
40.94%
47.76%
Dividend Yield
0%
0%
Shareholder Yield
-40.83%
-0.82%
1-Year Price Total Return
-35.35%
-34.27%
Beta (5-Year)
1.144
0.625
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $0.50
200-day SMA
Sell
Level $0.61
Bollinger Bands (100)
Sell
Level 0.37 - 0.61
Chaikin Money Flow
Sell
Level -722.4M
20-day SMA
Sell
Level $0.51
Relative Strength Index (RSI14)
Sell
Level 42.16
ADX Line
Sell
Level 23.9
Williams %R
Buy
Level -94.9861
50-day SMA
Sell
Level $0.46
MACD (12, 26)
Sell
Level 0.01
25-day Aroon Oscillator
Buy
Level 12
On Balance Volume
Neutral
Level 1.8B

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-4.4218)
Sell
CA Score (Annual)
Level (-2.8234)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.9025)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Stock Forecast FAQ

In the current month, VXRT has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VXRT average analyst price target in the past 3 months is $4.67.

  • Where Will Vaxart Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Vaxart share price will rise to $4.67 per share over the next 12 months.

  • What Do Analysts Say About Vaxart?

    Analysts are divided on their view about Vaxart share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vaxart is a Sell and believe this share price will drop from its current level to $2.00.

  • What Is Vaxart's Price Target?

    The price target for Vaxart over the next 1-year time period is forecast to be $4.67 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is VXRT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Vaxart is a Buy. 3 of 3 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of VXRT?

    You can purchase shares of Vaxart via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vaxart shares.

  • What Is The Vaxart Share Price Today?

    Vaxart was last trading at $0.44 per share. This represents the most recent stock quote for Vaxart. Yesterday, Vaxart closed at $0.44 per share.

  • How To Buy Vaxart Stock Online?

    In order to purchase Vaxart stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
92
BGL alert for Jul 3

Blue Gold [BGL] is down 20.3% over the past day.

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 1.3% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock